In Part 1 and of our blog series, we highlighted the importance of understanding neuroinflammation in neurodegenerative diseases. Today’s post looks at how CodePlex Secretome can address common challenges and provide a solution.
As we’ve discussed previously, neuroinflammation is a complex biological response to injured nervous tissue, playing a pivotal role in neurodegenerative diseases. With our cellular functional phenotyping, cellular differences can be uncovered and functional mechanisms in both neuroinflammation and neurotoxicity can be pinpointed.
The IsoPlexis CodePlex solution is designed to provide a faster and more streamlined approach to generating multiplexed bulk cytokine data via a fully automated end-to-end workflow. The CodePlex Secretome Solution unleashes super-powered and super-automated multiplexed proteomics in very low sample volumes to access insights immediately. With a faster and more streamlined approach, CodePlex offers a modular solution to bulk cytokine data analysis and minimizes variability from user input.
Below we highlight a recent study in which CodePlex technology was used to uncover insights into COVID-19.
Neurological Manifestations of COVID-19 in Patients: IsoPlexis’ Functional Proteomics Reveals Secretomic Signatures in CSF and Plasma
COVID-19, which is caused by the SARS-CoV-2 virus, is known as a respiratory disease; however neurological complications can occasionally be among the presenting symptoms in patients. In this study, researchers examined a 78-year-old immunocompromised woman whose mental status was altered after experiencing seizure-like activity. She was diagnosed with SARS-CoV-2 infection and associated neuroinflammation. The team analyzed cerebrospinal fluid (CSF) cytokines during infection and found a unique pattern of inflammation in CSF but no evidence of viral neuroinvasion.1
The use of IsoPlexis’ CodePlex Secretome revealed unique cytokine signatures in plasma and CSF from patients presenting with neurological disorders in COVID-19. The findings also suggested that neurologic symptoms such as encephalopathy and seizures may be the initial presentation of COVID-19. The researchers concluded that central nervous system inflammation may associate with neurologic manifestations of disease.2
Low Volume Highly Multiplexed Automated Immunoassays
CodePlex technology enables researchers to uniquely capture key measures of multiplexed bulk cytokine metrics in an automated matter. The CodePlex Secretome chips are used to optimize experimental conditions by enabling quick and cost-efficient population assays.
Be sure to look for Part 4 of our series as we provide highlights of informing targeted combination therapies with our Single-Cell Intracellular Proteomics.
- Farhadian S, Glick LR, Vogels CBF, Thomas J, Chiarella J, Casanovas-Massana A, Zhou J, Odio C, Vijayakumar P, Geng B, Fournier J, Bermejo S, Fauver JR, Alpert T, Wyllie AL, Turcotte C, Steinle M, Paczkowski P, Cruz CD, Wilen C, Ko AI, MacKay S, Grubaugh ND, Spudich S, Aoun Barakat L. Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19. Res Sq [Preprint]. 2020 May 12:rs.3.rs-28583. doi: 10.21203/rs.3.rs-28583/v1. Update in: BMC Neurol. 2020 Jun 18;20(1):248. PMID: 32702723; PMCID: PMC7336693.
- Proteomic Product Suite for Neuroinflammation. https://isoplexis.com/literature/isoplexis-proteomic-product-suite-for-neuroinflammation/.